Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22142119 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2POLBBLMMCOLN3LMNA | |
| SCHEMBL22142250 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2POLBBLMMCOLN3LMNA | |
| SCHEMBL22142011 | 0.81 | MAPK1 (0.37) | SMN1; SMN2THRB | |
| SCHEMBL22142000 | 0.81 | MAPK1 (0.37) | SMN1; SMN2THRB | |
| SCHEMBL22142007 | 0.81 | MAPK1 (0.37) | SMN1; SMN2THRB | |
| SCHEMBL22142001 | 0.79 | BLM (0.34) | POLBBLMMCOLN3LMNACHRM2 | |
| SCHEMBL22142012 | 0.79 | BLM (0.34) | POLBBLMMCOLN3LMNACHRM2 | |
| SCHEMBL22142008 | 0.79 | BLM (0.34) | POLBBLMMCOLN3LMNACHRM2 | |
| SCHEMBL22142280 | 0.72 | MAOA (0.31) | BLMMCOLN3 | |
| SCHEMBL22142277 | 0.72 | MAOA (0.31) | BLMMCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | SMN1; SMN2 2165/4885POLB 3721/4885BLM 3264/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | SMN1; SMN2 2165/4885POLB 3721/4885BLM 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.